Table 1—

Baseline characteristics of trial participants

AllDeveloped diabetes
Placebo/nicotinamide treatment group102/11155/50
Sex (male/female)127/8668/37
Age at randomization (years)11.66 (7.99–15.0)10.20 (7.33–13.6)
Pubertal group
    Prepubertal10462
    Early puberty (Tanner 2 and 3)4118
    Late puberty (Tanner 4 and 5)136
    Postpubertal3712
Islet autoantibodies
    ICA + 1 additional antibody347
    ICA + 2 additional antibodies6628
    ICA + 3 additional antibodies11370
FPIR (pmol/l)337 (181–546)207 (125–368)
120-min plasma glucose (mmol/l)5.7 (5.8–6.95)6.4 (5.1–7.6)
HOMA2-IR0.59 (0.35–0.87)0.61 (0.36–0.82)
Weight (SDS)0.22 (−0.40 to 0.88)0.32 (−0.40 to 0.98)
Height (SDS)0.24 (−0.28 to 0.88)0.24 (−0.46 to 0.88)
BMI (SDS)0.01 (−0.65 to 0.77)0.05 (−0.72 to 0.92)
  • Data are n or median (interquartile range).